secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001411685-25-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen appoints Elissa Cote as Chief Corporate Development Officer
--------------------------------------------------------------------

- Cote appointed CCDO effective June 23, 2025, to lead strategic partnerships and pherine platform advancement.
- Nearly 30 years biopharma BD experience; previously Chief Strategy/BD Officer at Mallinckrodt Pharmaceuticals.
- Received inducement option for 150,000 shares at June 23 closing price; vests 25% year one, then monthly over 36 months.
- Pipeline includes five intranasal pherine candidates targeting six CNS disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000048/0001411685-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000048/vtgn-20250623.htm
  HTML page:      https://secwatch.observer/filing/0001411685-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer